HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
World Aging & Longevity Conference
October 08-10, 2026
Longevity Drugs
Longevity Drugs
Longevity drugs are pharmacological agents designed to influence aging pathways and delay onset of age-related decline. These drugs target conserved biological mechanisms such as nutrient sensing, mitochondrial function, and cellular maintenance systems. Longevity drugs aim to improve resilience, reduce multimorbidity, and preserve functional capacity. Rather than treating individual diseases, they address shared drivers of aging. Longevity drug development integrates geroscience research with translational medicine. Understanding longevity drugs highlights pharmacological modulation of aging biology as a promising strategy for extending healthspan.
Committee Members
Kenneth R Pelletier
University of California School of Medicine, United States
Thomas J Webster
Brown University, United States
Jason Beckwith
BioTalent, United Kingdom WALC 2026 Speakers
Sergey Suchkov
N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Jose Cordeiro Mateo
International Longevity Summit, Spain
Ashot Khachatryan
National Academy of Sciences of the Republic of Armenia, Armenia
Utpol Das
University of Texas Medical Branch at Galveston, United StatesSubmit your abstract Today
Title : Change your genes – Change your life: Epigenetics of longevity
Kenneth R Pelletier, University of California School of Medicine, United States
Title : Improving mobility and health in over 45,000 humans using nanomedicine
Thomas J Webster, Brown University, United States
Title : An introduction to alchemical facial acupuncture: Sparking the shen
Mary Elizabeth Wakefield, Chi-Akra Center for Ageless Aging, United States
Title : Decoding the secret of longevity through big data: Noncoding RNAs—not proteins—drive animal lifespan evolution
Anyou Wang, DIFIBER LLC, United States
Title : Aspirin guided by coronary artery calcium scoring for primary prevention in persons with subclinical coronary heart disease
Arthur J Siegel, McLean Hospital, United States
Title : When BMI misleads: Integrating body composition, biomarkers, and personalized interventions for cardiometabolic healthspan in aging Asian and European cohorts
Narendra Kumar, HeartbeatsZ Academy, United Kingdom